EYPTEyePoint, Inc.

Graham Holdings (GHC) was a bearish price surprise on Monday, down 2.2%. At the same time, Biglari Holdings (BH.A) was a bullish price surprise, up 3.56%. Both holding companies have diversified businesses. The bear is the bet.

EyePoint's (EYPT) phase 3 Lugano trial's failure to meet its primary endpoint raises concerns about

GlobalData highlighted EyePoint’s Duravyu as a notable drug set to enter the wet AMD market by 2034.

Norwegian Cruise downgrade, Duolingo upgraded: Wall Street's top analyst calls

RBC Capital said that even if EyePoint’s second Phase 3 study delivers positive results, questions would remain over whether the U.S. Food and Drug Administration would approve the treatment based on a single trial.

Interest in EyePoint (EYPT) has focused on fresh topline data from the Phase 3 LUGANO trial of DURAVYU for wet age related macular degeneration, after the study missed its primary non inferiority endpoint but showed meaningful secondary outcomes. See our latest analysis for EyePoint. The LUGANO update has coincided with a sharp reset in EyePoint's share price. The stock closed at $4.87 after a 1 day share price return that declined 66.98%. This contributed to a year to date share price return...

EyePoint Pharmaceuticals recently reported that its pivotal Phase 3 LUGANO trial of DURAVYU for wet age-related macular degeneration did not achieve the primary non-inferiority endpoint versus aflibercept, while posting clinically meaningful gains in treatment burden reduction and maintaining a favorable safety profile. The company now faces a critical juncture as it pivots investor focus to the upcoming LUCIA Phase 3 readout and a potential US Food and Drug Administration filing in 2027,...

The sell-offs followed a failed trial, a massive recall, and a CEO's exit.

EyePoint Pharmaceuticals said on Monday that its late-stage trial of DURAVYU, an experimental long-lasting eye implant for wet age-related macular degeneration, missed its main goal.

EyePoint stock crashed Monday after its eye disease treatment, Duravyu, missed the mark in a final-phase study.

Duravyu, EyePoint’s candidate for wet age-related macular degeneration, misses the mark, but muddled trial data may be to blame.

Healthcare stocks were mixed Monday afternoon, with the NYSE Healthcare Index up nearly 0.1% and the

Eyepoint Pharmaceuticals (NASDAQ:EYPT) reported topline results from LUGANO, the first of two Phase III trials evaluating DURAVYU, a vorolanib intravitreal insert, in patients with wet age-related macular degeneration, or wet AMD. The study did not meet its primary non-inferiority endpoint in the fu

The Nasdaq Composite was up, while the Dow Jones Industrial Average and S&P 500 Index were down in l

EyePoint (NASDAQ:EYPT) reported that its Phase 3 LUGANO trial of DURAVYU in wet age-related macular degeneration did not achieve its primary endpoint in the full dataset, although the company reported positive secondary outcomes and an ad hoc analysis in which DURAVYU was non-inferior to aflibercept. The Phase 3 LUGANO trial result puts added importance on the second pivotal LUCIA study, due to report topline data in the fourth quarter of 2026, as EyePoint continues to target a potential DURAVYU

EyePoint (EYPT) delivered earnings and revenue surprises of -18.48% and +102.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Ocular Therapeutix's (OCUL) regulatory plans for Axpaxli in wet age-related macular degeneration rem

Beam Therapeutics (BEAM) delivered earnings and revenue surprises of -18.00% and -98.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

EyePoint (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.